1. S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB. (23rd June 2022) Authors: Al-Sawaf, O.; Jin, H. Y.; Zhang, C.; Choi, Y.; Balasubramanian, S.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; Kreuzer, K.-A.; Chyla, B.; Paulson, J.; Eichhorst, B.; Stilgenbauer, S.; Jiang, Y.; Hallek, M.; Fischer, K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY. (23rd June 2022) Authors: Al-Sawaf, O.; Zhang, C.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; Kreuzer, K.-A.; Chyla, B.; Eichhorst, B.; Jiang, Y.; Stilgenbauer, S.; Hallek, M.; Fischer, K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗